Posted on April 23,$INNOVENT BIO (01801.HK)$It rose more than 5% in the afternoon. As of press release, it had risen 6.48% to HK$36.15, with a turnover of HK$215 million.

According to the news, on April 22, Cinda Biopharmaceuticals announced that dabotan (pemitinib tablets) was approved for marketing by the Macau Drug Administration (ISAF), China for adult patients with locally advanced or metastatic cholangiocarcinoma whose disease worsened after receiving systemic treatment and whose tumors had FGFR2 fusion or rearrangement.

Guosheng Securities previously stated that at present, the company has commercialized 10 products, submitted NDA for 3 products, 5 products have entered Phase 3/critical clinical trials, and 18 products are in early clinical trials. The field of non-oncology includes metabolic & cardiovascular, endocrinology, and ophthalmology. PCSK9 monoclonal antibodies have been approved for marketing, and the NDA (GLP-1R/GCGR) has been accepted, and IGF-1R monoclonal antibodies and IL23p19 monoclonal antibodies are expected to be declared within 2024. A major single product echelon for chronic diseases has been formed, which will help the company achieve the sales target of 20 billion products within 5 years.